希腊德尔塔和奥密克戎波期间住院COVID-19患者中全程(加强)疫苗接种对严重结局和工作缺勤的有效性
研究纳入2021年11月15日至2022年4月17日希腊住院COVID-19患者1138例,评估全程(加强)疫苗接种对严重结局和工作缺勤的有效性。结果显示,与未接种者相比,全程接种者入住ICU、机械通气、死亡风险及住院时间均降低,且工作缺勤时间更短。
要点
- 全程接种者较未接种者入住ICU的调整相对风险为0.49(95%CI 0.29-0.84)。
- 全程接种者较未接种者机械通气的调整相对风险为0.43(95%CI 0.23-0.80)。
- 未接种者工作缺勤时间较部分或全程接种者更长(平均20.1天 vs 12.3天和17.3天,P=0.03)。
核心结论
- 全程(加强)COVID-19疫苗接种可预防严重结局、延长住院时间和延长工作缺勤。
研究设计与样本
- 研究期间为2021年11月15日至2022年4月17日,纳入住院COVID-19患者1138例(平均年龄66.6岁),其中826例(72.6%)有至少1种合并症。
- 全程疫苗接种定义为基础接种后至少6个月接种加强针。
主要发现
- 1138例患者中,75例(6.6%)入住ICU,64例(5.6%)接受机械通气,172例(15.1%)死亡;全程接种386例(33.9%),部分接种172例(15.1%),未接种580例(51%)。
- 未接种者工作缺勤时间较部分或全程接种者更长(平均20.1天 vs 12.3天和17.3天,P=0.03)。
- 与未接种者相比,全程接种者入住ICU的调整相对风险为0.49(95%CI 0.29-0.84),机械通气的调整相对风险为0.43(95%CI 0.23-0.80),死亡的调整相对风险为0.57(95%CI 0.42-0.78),住院时间的调整相对风险为0.79(95%CI 0.70-0.89)。
- 全程疫苗对入住ICU的调整有效性为48.8%(95%CI 42.7%-54.9%),对机械通气的调整有效性为55.4%(95%CI 52.0%-56.2%),对死亡的调整有效性为22.6%(95%CI 7.4%-34.8%)。
- 对于有至少3种合并症的患者,疫苗对入住ICU的有效性为56.2%(95%CI 43.9%-67.1%),对机械通气的有效性为60.2%(95%CI 53.7%-65.4%),对死亡的有效性为43.9%(95%CI 19.9%-59.7%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: We estimated vaccine effectiveness (VE) of full (booster) vaccination against severe outcomes in hospitalized COVID-19 patients during the Delta and Omicron waves. METHODS: The study extended from November 15, 2021 to April 17, 2022. Full vaccination was defined as a primary vaccination plus a booster ≥ 6 months later. RESULTS: We studied 1138 patients (mean age: 66.6 years), of whom 826 (72.6 %) had ≥ 1 comorbidity. Of the 1138 patients, 75 (6.6 %) were admitted to intensive care unit (ICU), 64 (5.6 %) received mechanical ventilation, and 172 (15.1 %) died. There were 386 (33.9 %) fully vaccinated, 172 (15.1 %) partially vaccinated, and 580 (51 %) unvaccinated patients. Unvaccinated patients were absent from work for longer periods compared to partially or fully vaccinated patients (mean absence of 20.1 days versus 12.3 and 17.3 days, respectively; p-value = 0.03). Compared to unvaccinated patients, fully vaccinated patients were less likely to be admitted to ICU [adjusted relative risk (ARR: 0.49; 95 % CI: 0.29-0.84)], mechanically ventilated (ARR: 0.43; 95 % CI: 0.23-0.80), and die (ARR: 0.57; 95 % CI: 0.42-0.78), while they were hospitalized for significantly shorter periods (ARR: 0.79; 95 % CI: 0.70-0.89). The adjusted full VE was 48.8 % (95 % CI: 42.7 %-54.9 %) against ICU admission, 55.4 % (95 % CI: 52.0 %-56.2 %) against mechanical ventilation, and 22.6 % (95 % CI: 7.4 %-34.8 %) against death. For patients with ≥ 3 comorbidities, VE was 56.2 % (95 % CI: 43.9 %-67.1 %) against ICU admission, 60.2 % (95 % CI: 53.7 %-65.4 %) against mechanical ventilation, and 43.9 % (95 % CI: 19.9 %-59.7 %) against death. CONCLUSIONS: Full (booster) COVID-19 vaccination conferred protection against severe outcomes, prolonged hospitalization, and prolonged work absenteeism.
引用
- Maltezou HC, Basoulis D, Bonelis K, et al. Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece. Vaccine. 2023. PMID: 36740558. doi:10.1016/j.vaccine.2023.01.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。